ZYME - Zymeworks Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

17.94

+0.24 (+1.36%)

As of 12:20PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	17.70
Open	17.70
Bid	17.94 x 1100
Ask	18.10 x 800
Day's Range	17.73 - 18.29
52 Week Range	6.25 - 18.29
Volume	74,591
Avg. Volume	40,454

Market Cap	460.518M
Beta	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-0.64
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	16.20

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wire8 days ago
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement.
Business Wire12 days ago
Zymeworks to Present at the UBS Global Healthcare Conference 2018
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming UBS Global Healthcare Conference taking place May 21-23, 2018 in New York, NY, USA.
Business Wire21 days ago
Zymeworks Reports 2018 First Quarter Financial Results
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the quarter ended March 31, 2018.
Business Wire22 days ago
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co.
Business Wire27 days ago
Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that the abstract highlighting new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for an oral presentation at the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1 through 5, 2018. The oral presentation, entitled “Single Agent Activity of ZW25, a HER2 Targeted Bispecific Antibody, in Heavily Pretreated HER2 Expressing Cancers,” is scheduled for Friday June 1, 2018 at 2:45 pm CT during the session on Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics in room S406.
Business Wire29 days ago
Zymeworks and Celgene Expand Bispecific Antibody Collaboration
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform. “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and we are delighted to expand and continue our relationship with them,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO.
Business Wirelast month
Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today presented preclinical data on ZW49, its lead bispecific antibody-drug conjugate candidate and its ZymeLink ADC platform.
Simply Wall St.2 months ago
Was Zymeworks Inc’s (TSE:ZYME) Earnings Growth Better Than The Industry’s?
When Zymeworks Inc’s (TSX:ZYME) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I used wereRead More...
Business Wire2 months ago
Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that ZW49 is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics.
Business Wire2 months ago
Zymeworks Reports 2017 Year-End Financial Results
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2017.
Business Wire2 months ago
Zymeworks to Present at Barclays 2018 Global Healthcare Conference
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 13-15, 2018 in Miami Beach, Florida.
Business Wire3 months ago
Zymeworks Opening Clinical Sites in Canada
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the addition of new clinical sites in Canada and the United States for its ongoing adaptive Phase 1 study of the company’s lead clinical candidate, ZW25.
Business Wire4 months ago
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today provided key accomplishments from the past year and announced priorities for 2018.
PR Newswire5 months ago
Lifshitz & Miller LLP Announces Investigation of Alon USA Partners, LP, Amplify Snack Brands, Inc., Kindred Healthcare, Inc., Pinnacle Entertainment, Inc., Regal Entertainment Group, Sigma Designs, Inc. and Zymeworks Inc.
NEW YORK , Dec. 28, 2017 /PRNewswire/ -- Alon USA Partners, LP (ALDW) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed ...
Business Wire5 months ago
ZYME INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Zymeworks Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Zymeworks Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
PR Newswire5 months ago
Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information
SAN DIEGO , Dec. 15, 2017 /PRNewswire/ -- Johnson Fistel, LLP, is investigating potential violations of the federal securities laws by Zymeworks Inc. (NYSE: ZYME) ("Zymeworks") and certain of ...
Business Wire6 months ago
Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, today presented the completed dose escalation portion of its Phase 1 study of ZW25, a novel Azymetric™ bispecific antibody targeting two distinct domains of the HER2 receptor.
ACCESSWIRE6 months ago
Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
Research Desk Line-up: Intrexon Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Zymeworks ...
Business Wire6 months ago
Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced it will present at the upcoming 2017 Stifel Healthcare Conference taking place November 14-15, 2017 in New York City, New York.
Business Wire6 months ago
Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced it has executed a licensing agreement with Janssen Biotech, Inc.
Business Wire6 months ago
Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2017.
Business Wire8 months ago
Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks’ Azymetric™ Platform into Preclinical Development
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, today announced that Merck has provided formal notification of their plans to advance a bispecific drug candidate into preclinical development.
Business Wire8 months ago
Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today provided additional data from the dose escalation portion of its Phase 1 study of ZW25, a novel Azymetric™ bispecific antibody targeting two distinct domains of the HER2 receptor.
Benzinga8 months ago
2 Names Barclays Is Now Bearish On In Biotech
z,pz.Even as Barclays initiated coverage of the U.S. small- and mid-cap biotechnology industry with a positive view, it was bearish on Cascadian Therapeutics Inc (USA) (NASDAQ: CASC ) and Zymeworks Inc ...
Business Wire8 months ago
Zymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results
Zymeworks Inc. , a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced that it will be presenting updated Phase 1 clinical trial dose escalation data at the European Society for Medical Oncology Congress, being held from September 8-12, 2017 in Madrid, Spain.